Rapid, Simple, Quantitative, and Highly Sensitive Antibody Detection for Lyme Disease

Neurobiology and Pain Therapeutics Section, 49 Convent Drive, Building 49, Room 1C20, NIDCR, NIH, Bethesda, MD 20892-4410, USA.
Clinical and vaccine Immunology: CVI (Impact Factor: 2.47). 06/2010; 17(6):904-9. DOI: 10.1128/CVI.00476-09
Source: PubMed


There is currently a need for improved serological tests for the diagnosis and monitoring of Lyme disease, an infection caused
by Borrelia burgdorferi. In the present study, we evaluated luciferase immunoprecipitation systems (LIPSs) for use for profiling of the antibody
responses to a panel of B. burgdorferi proteins for the diagnosis of Lyme disease. Initially, serum samples from a cohort of patients and controls (n = 46) were used for training and were profiled by the use of 15 different B. burgdorferi antigen constructs. For the patient sera, the antibody responses to several B. burgdorferi antigens, including VlsE, flagellin (FlaB), BmpA, DbpA, and DbpB, indicated that the antigens had high levels of immunoreactivity.
However, the best diagnostic performance was achieved with a synthetic protein, designated VOVO, consisting of a repeated
antigenic peptide sequence, VlsE-OspC-VlsE-OspC, Analysis of an independent set of serum samples (n = 139) used for validation showed that the VOVO LIPS test had 98% sensitivity (95% confidence interval [CI], 93% to 100%;
P < 0.0001) and 100% specificity (95% CI, 94% to 100%; P < 0.0001). Similarly, the C6 peptide enzyme-linked immunosorbent assay (ELISA) also had 98% sensitivity (95% CI, 93% to 100%;
P < 0.0001) and 98% specificity (95% CI, 90% to 100%; P < 0.0001). Receiver operating characteristic analysis revealed that the rates of detection of Lyme disease by the LIPS test
and the C6 ELISA were not statistically different. However, the VOVO LIPS test displayed a wide dynamic range of antibody
detection spanning over 10,000-fold without the need for serum dilution. These results suggest that screening by the LIPS
test with VOVO and other B. burgdorferi antigens offers an efficient quantitative approach for evaluation of the antibody responses in patients with Lyme disease.

Download full-text


Available from: Michael Iadarola,
  • Source
    • "In resource-limited settings wherein health-care infrastructure is weak, there is an urgent need for rapid, sensitive and cost affordable point-of-care tests (POCT) for the detection of diseases 1-3. This challenge is particularly important for preventing the transfer of infectious diseases such as hepatitis B virus infection and for improving the standards of living 4-6. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Simple and sensitive detection of infectious disease at an affordable cost is urgently needed in developing nations. In this regard, the dot blot immunoassay has been used as a common protein detection method for detection of disease markers. However, the traditional signal reporting systems, such as those using enzymes or gold nanoparticles lack sensitivity and thus restrict the application of these methods for disease detection. In this study, we report a simple and sensitive detection method for the detection of infectious disease markers that couples the dot-blot immunoassay with quantum dots nanobeads (QDNBs) as a reporter. First, the QDNBs were prepared by an oil-in-water emulsion-evaporation technique. Because of the encapsulation of several QDs in one particle, the fluorescent signal of reporter can be amplified with QDNBs in a one-step test and be read using a UV lamp obviating the need for complicated instruments. Detection of disease-associated markers in complex mixture is possible, which demonstrates the potential of developing QDNBs into a sensitive diagnostic kit.
    Theranostics 01/2014; 4(3):307-15. DOI:10.7150/thno.8007 · 8.02 Impact Factor
  • Source
    • "Third, the anti-HMOAstV-C capsid antibody titers detected by LIPS assay in human samples was substantially higher than the background binding associated with mock protein A/G beads alone. This magnitude is comparable to those seen by LIPS against other infection agents such as Borrelia burgdorferi [27] and Kaposi Sarcoma associated virus [28]. Our strategy of using buffer blanks instead of seronegative uninfected samples has been used in other seroepidemiologic investigations and provide comparable diagnostic thresholds as seronegative samples [24], [29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Molecular identification of a microbe is the first step in determining its prevalence of infection and pathogenic potential. Detection of specific adaptive immune responses can provide insights into whether a microbe is a human infectious agent and its epidemiology. Here we characterized human anti-IgG antibody responses by luciferase immunoprecipitation systems (LIPS) against two protein fragments derived from the capsid protein of the novel HMOAstV-C astrovirus. While antibodies to the N-terminal fragment were not informative, the C-terminal capsid fragment of HMOAstV-C showed a high frequency of immunoreactivity with serum from healthy blood donors. In contrast, a similar C-terminal capsid fragment from the related HMOAstV-A astrovirus failed to show immunoreactivity. Detailed analysis of adult serum from the United Sates using a standardized threshold demonstrated HMOAstV-C seropositivity in approximately 65% of the samples. Evaluation of serum samples from different pediatric age groups revealed that the prevalence of antibodies in 6-12 month, 1-2 year, 2-5 year and 5-10 year olds was 20%, 23%, 32% and 36%, respectively, indicating rising seroprevalence with age. Additionally, 50% (11/22) of the 0-6 month old children showed anti-HMOAstV-C antibody responses, likely reflecting maternal antibodies. Together these results document human humoral responses to HMOAstV-C and validate LIPS as a facile and effective approach for identifying humoral responses to novel infectious agents.
    PLoS ONE 08/2011; 6(8):e22576. DOI:10.1371/journal.pone.0022576 · 3.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Synthetic biology involves the engineering of proteins, signaling pathways and even whole organisms using modular designs and formats. A major tool of synthetic biology is artificial gene synthesis, which provides a direct means from a conceptualized DNA sequence to the corresponding physical DNA for the construction of a variety of biological components. To date, synthetic biology has often been used to answer fundamental questions in basic research, but now is poised to greatly enhance translational research. In this review, we discuss several translational applications of synthetic biology including the construction of novel diagnostics and vaccines, development of new synthetic pathways for drug screening and biosynthesis, and the creation of engineered viruses and microbes to fight human disease. Together these and other novel translational applications of artificial gene synthesis and synthetic biology have the opportunity to make major advances for improving human health.
    American Journal of Translational Research 01/2010; 2(4):381-9. · 3.40 Impact Factor
Show more